PT Medco Energi Internasional Tbk
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTGIF research report →
Price Chart
About the company
PT Medco Energi Internasional Tbk operates as a comprehensive energy and natural resources enterprise, with its primary focus on the exploration and extraction of oil and gas. Domestically, the company manages an extensive portfolio in Indonesia, comprising 11 exploration and production blocks, a single development block, and four exploration blocks situated across key regions such as Natuna, Sumatra, Kalimantan, Java, and Sulawesi. On the international front, it maintains oil and gas interests in Vietnam, Thailand, Oman, Libya, Yemen, Malaysia, Mexico, and Tanzania.
- CEO
- Roberto Lorato
- IPO
- 2013
- Employees
- 3,327
- HQ
- Jakarta, ID
Get TickerSpark's AI analysis on PTGIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.99B
- P/E
- 4.63
- Fwd P/E
- 4.11
- PEG
- 0.07
- P/S
- 0.59
- P/B
- 0.68
- EV/EBITDA
- 3.10
- Div Yield
- 4.70%
- Gross Margin
- 40.56%
- Op Margin
- 30.90%
- Net Margin
- 12.70%
- ROE
- 15.26%
- ROIC
- 5.25%
Latest fiscal year · YoY change
- Revenue
- $2.40B-0.2%
- Gross Profit
- $916.73M-1.8%
- Op Income
- $694.34M
- Net Income
- $99.69M-72.9%
- EPS
- $0.00-72.8%
- OCF Growth
- -25.7%
- FCF Growth
- -53.2%
- 52W High
- $0.12
- 52W Low
- $0.06
- 50D MA
- $0.08
- 200D MA
- $0.09
- Beta
- -0.04
- RSI (14)
- 95
- Avg Volume
- 9
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medco Energi delivered strong first-half 2026 growth in production, EBITDA, and net income, while keeping leverage low and reaffirming full-year guidance despite planned second-half maintenance.· September 30, 2026
- Production rose to 170,100 boe/d, up 19% year over year and already tracking above full-year guidance.
- EBITDA increased 30.7% to USD 805.1 million and net income jumped to USD 275.3 million from USD 30.7 million last year.
- Cash costs stayed low at USD 8.4/boe, well below the full-year ceiling of USD 10/boe.
- Restricted group net debt/EBITDA improved to 1.4x from 2.0x at end-2025, with cash and equivalents at USD 1.4 billion.
- Management raised 2026 CapEx for oil and gas to USD 450-475 million and power CapEx to as much as USD 50 million to accelerate projects, not because of overruns.
For first half 2026, revenue was USD 1.4 billion, up 23.4%; EBITDA was USD 805.1 million, up 30.7%; and net income was USD 275.3 million versus USD 30.7 million a year ago. EBITDA margin expanded from 53.7% to 56.9%. Production reached 170,100 barrels of oil equivalent per day, up 19% year over year, while power sales rose 16.5% to 2,323 GWh. Cash costs were USD 8.4 per boe, and operating cash flow was USD 514.7 million, up 46.6%. Restricted group net debt was USD 2.1 billion and restricted group net debt/EBITDA improved to 1.4x from 2.0x at end-2025. Full-year guidance was reaffirmed: production remains at 165,000-170,000 boe/d, cash cost below USD 10/boe, and power sales on plan. Oil and gas CapEx guidance was raised to USD 450 million to USD 475 million, and power CapEx increased to as much as USD 50 million; management said this reflects accelerated investment in Sakakemang and Batam, not cost overrun.
Ronald Gunawan stressed continuity in strategy despite the new management team, emphasizing the same pillars of operational excellence, cost discipline, disciplined capital allocation, balance sheet strength, and selective growth. He framed the first-half result as evidence that the portfolio strategy is working: higher production, stronger earnings, and a more flexible balance sheet. He also highlighted the company’s diversified model across oil and gas, clean power, and the AMMN stake as a way to create resilient long-term value.
Benny Setiawan focused on the financial leverage from higher volumes and stable costs, noting that EBITDA outpaced revenue because more barrels flowed through a largely fixed cost base. He cited revenue of USD 1.4 billion, EBITDA of USD 805.1 million, net income of USD 275.3 million, operating cash flow of USD 514.7 million, and cash and equivalents of USD 1.4 billion. He also pointed to restricted group net debt/EBITDA at 1.4x, a mid-cycle leverage view of 1.9x at USD 65/bbl, and fixed charge coverage of 5.6x versus a 3x floor, arguing the company has room to fund growth while staying within policy.
Analysts pressed management on whether the USD 2.6 billion liquidity buffer signaled an acquisition plan; Sanjeev Bansal said Medco is always evaluating opportunities but will only pursue sizable, high-margin producing assets that fit its infrastructure and risk framework, with no comment on any specific deal. Questions also focused on the audit of first half 2026 and on why production guidance was not raised; Benny said the audit was completed mainly to preserve flexibility for future corporate actions, while Amri said management is keeping guidance because second-half maintenance and expected declines offset the strong first-half run-rate. Another concern was whether PSC extension delays could hurt production; Ronald said 2026 production would not be affected and pointed to sufficient time and a track record of extensions.
The call showed execution across multiple projects, with management saying five developments in three countries came on or near plan and that production is now above full-year guidance pace. Costs remain tightly controlled, leverage improved, and the company has ample liquidity to keep investing while still deleveraging. Management also sounded confident that the portfolio of oil and gas, power, and AMMN provides both growth and resilience.
Management repeatedly flagged second-half maintenance and expected production declines as reasons not to raise guidance despite the strong first half. Reserve replacement remains an ongoing priority, and several PSC extensions are still in the administrative process, even if management said they do not see a 2026 production impact. The company also acknowledged higher CapEx needs as it accelerates Sakakemang and Batam, which could increase spending even if management insists the program is commercially justified.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 25.0%
- Shares Outstanding
- 24.73B
- Float Shares
- 6.19B
Our PTGIF coverage
Recent articles, reports, and earnings notes.
No research on PTGIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTGIF report →